Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658826 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Phase 2 study, sponsored by AiCuris Anti-infective Cures.
- Terminated
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT01658826 is a Phase 2 study that was terminated before completion, run by AiCuris Anti-infective Cures. The registered enrollment target is 91 participants.
The verdict
NCT01658826, a Phase 2 study, was terminated before completion, sponsored by AiCuris Anti-infective Cures.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.
Interventions
- DRUG Valacyclovir
- DRUG AIC316
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01658826
The ClinicalTrials.gov registry entry for NCT01658826 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AiCuris Anti-infective Cures, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valacyclovir is the first listed.
NCT01658826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01658826 about?
NCT01658826 is a clinical study titled "Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes". The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.
What is the current status of trial NCT01658826?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2012-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01658826?
The interventions under investigation include: Valacyclovir (DRUG), AIC316 (DRUG).
Who is sponsoring clinical trial NCT01658826?
This trial is sponsored by AiCuris Anti-infective Cures, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.